Core Insights - The company, Zhaoke Ophthalmology (6622.HK), has three core drug candidates that have entered the New Drug Application (NDA) stage, with expected approvals in China in the second and third quarters of next year [1] - The two formulations of atropine eye drops at concentrations of 0.01% and 0.02% are aimed at controlling the progression of myopia in adolescents [1] - Zhaoke's 0.01% atropine eye drops, branded as "Mei Le Tong," is the second product in the industry to receive an application acceptance, following the approval of a similar product by competitor Xingqi Eye Pharmaceutical last March [1] Product Comparison - Zhaoke's COO, Dai Xiangrong, noted that their product has a pH value close to 6, making it more neutral and less irritating compared to the competitor's product [1] - The industry estimates that Xingqi's 0.01% atropine eye drops generated sales of over 700 million RMB within nine months of its launch [1] - Although Zhaoke did not provide a specific sales target for its 0.01% atropine eye drops, it indicated that it would use the competitor's sales as a benchmark [1]
兆科眼科：料三款核心候选药物明年二三季在中国内地获批上市